Ozempic for prediabetes: does it work?

It is prescribed off-label — no semaglutide product is FDA-approved specifically for prediabetes. The evidence behind the off-label use is strong, though: in the large weight-loss trials of semaglutide 2.4 mg (Wegovy dose), most participants who had prediabetes at the start returned to normal blood sugar, and semaglutide substantially reduced progression to type 2 diabetes. Whether medication is right for your prediabetes — versus lifestyle changes first — is a decision for your clinician.

In trials, it moved most people from prediabetes back to normal blood sugar. Pooled data from the STEP program found roughly 84–90% of people with prediabetes at baseline reverted to normoglycemia on semaglutide 2.4 mg, versus about 48–70% on placebo, over 68 weeks. Much of this is driven by weight loss and improved insulin sensitivity. "Reverse" can be misleading, though — prediabetes can return if weight is regained after stopping, so it is better thought of as controlling the underlying drivers than a permanent cure.

The evidence points that way. In the SELECT trial, about two-thirds of the 17,604 participants had prediabetes at the start, and semaglutide reduced progression to (biochemically defined) diabetes by roughly 73% over about four years. So beyond lowering current blood sugar, it appears to delay or prevent the transition to full diabetes in high-risk people — though, again, this was studied at the higher weight-loss dose and the benefit depends on staying on treatment.

The American Diabetes Association's front-line recommendation for prediabetes is intensive lifestyle change — a 5–7% weight loss and regular physical activity meaningfully delay progression to type 2 diabetes, and metformin is considered for certain higher-risk people. The ADA positions GLP-1 medications (and dual GIP/GLP-1 drugs) as preferred weight-management pharmacotherapy where medication for weight is indicated, but the first step for prediabetes remains lifestyle, not a GLP-1 prescription.

If you have prediabetes plus overweight/obesity and lifestyle changes haven't been enough, it is reasonable to discuss medication options, including GLP-1s, with your clinician — the trial data are genuinely encouraging. But it is off-label for prediabetes, these are prescription drugs with real risks and costs, and lifestyle change remains the foundation. Your doctor can weigh your individual risk, weight, and other conditions.

Any one of three results puts you in the range: an A1C of 5.7 to 6.4 percent, a fasting glucose of 100 to 125 mg/dL, or a 2-hour glucose of 140 to 199 mg/dL on an oral glucose tolerance test. Below those is normal; above them is diabetes. A single borderline result is usually repeated before anything is concluded, so one reading is a data point rather than a diagnosis. People often assume prediabetes from weight or symptoms — it is defined by the numbers.

A structured lifestyle program. In the landmark Diabetes Prevention Program trial, adults with prediabetes were randomized to an intensive lifestyle program, metformin, or placebo; over roughly three years the lifestyle program cut progression to type 2 diabetes by about 58 percent and metformin by about 31 percent, with lifestyle outperforming the drug — most strongly in older participants. That is why prevention programs, not medication, are first-line in prediabetes. CDC-recognized programs are widely available and covered by many plans, including a Medicare benefit for eligible beneficiaries.

Rarely on the basis of prediabetes alone. Coverage generally follows an FDA-approved indication — type 2 diabetes, or weight management where the plan includes weight-loss drugs — and prediabetes is neither. In practice you either qualify through weight-management criteria (typically a BMI threshold, often with a qualifying comorbidity), or your plan excludes weight-loss drugs entirely, in which case no clinical evidence about prediabetes changes that because it is a benefit-design decision rather than a medical one, or you pay cash.